2022 World Conference on Lung Cancer (ePosters)-EP16.02-026. Dynamic Change of Indoleamine 2,3-dioxygenase Activity Predicts Survival in Radiotherapy- Received Unresectable Stage III NSCLC

EP16.02-026. Dynamic Change of Indoleamine 2,3-dioxygenase Activity Predicts Survival in Radiotherapy- Received Unresectable Stage III NSCLC

Back to course

Pdf Summary

In this study, the researchers aimed to investigate the association between the dynamic change of Indoleamine 2,3-dioxygenase (IDO) activity and survival outcomes in stage III non-small cell lung cancer (NSCLC) patients who received radiotherapy. IDO is an enzyme that converts tryptophan to kynurenine and suppresses anti-tumor immune responses.<br /><br />The study included 119 NSCLC patients, of which 115 were stage III. The researchers measured the serum levels of kynurenine and tryptophan before the initiation of radiotherapy. They calculated the systemic IDO activity by dividing kynurenine by tryptophan ratio.<br /><br />The results showed that there was no significant change in serum IDO activity at different time points during radiotherapy. However, the changing pattern of the kynurenine to tryptophan ratio was categorized into four groups: constant decrease, increase followed by decrease, constant increase, and decrease followed by increase.<br /><br />Patients whose kynurenine to tryptophan ratio continuously decreased or initially increased and then decreased were defined as the "good-change" group. Multivariate analysis revealed that being in the "good-change" group was the only independent protective factor for overall survival, progression-free survival, and local control. Furthermore, a high pre-radiation kynurenine to tryptophan ratio trended towards shorter overall survival.<br /><br />In conclusion, favorable changes in IDO activity during radiotherapy were associated with better overall survival, progression-free survival, and local control in stage III NSCLC patients. Therefore, IDO activity may serve as a promising biomarker for prognosis in these patients.

Asset Subtitle

Linfang Wu

Meta Tag

Speaker Linfang Wu

Topic Tumour Biology and Biomarkers - Minimally Invasive Biomarkers

Keywords

Indoleamine 2,3-dioxygenase

IDO activity

survival outcomes

stage III non-small cell lung cancer

NSCLC patients

radiotherapy

kynurenine

tryptophan

systemic IDO activity

overall survival